Development of effective new treatments for multiple myeloma.
Anderson
Kenneth C
KC
Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu
Pazdur
Richard
R
Farrell
Ann T
AT
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015195:Drug Design; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000503:physiopathology*; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib